Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Iomab-B for the treatment of Refractory and Relapsed Acute Myeloid Leukaemia

Drug (Brand/Generic)

Iomab-B

Company

Actinium Pharmaceuticals

Therapy Class

Monoclonal antibody

Current Indication

Refractory and Relapsed Acute Myeloid Leukaemia

Market Sector

Oncology

Development Status

Under review in US and Europe
Expand

Go Top